54 patents
Utility
Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
16 Jan 24
This invention relates to compounds, compositions, and methods useful for reducing Glycolate Oxidase (HAO1) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. Brown, Henryk T. Dudek
Filed: 25 Jan 21
Utility
Double-stranded nucleic acid inhibitor molecules modified with Tm-increasing nucleotides
16 Jan 24
Provided herein are double-stranded nucleic acid inhibitor molecules having a sense strand with a stem loop structure and an antisense strand, where the stem portion of the stem loop structure contains one or more Tm-increasing nucleotides.
Weimin Wang, Naim Nazef, Bob Dale Brown
Filed: 11 Apr 19
Utility
Reducing beta-catenin and IDO expression to potentiate immunotherapy
14 Nov 23
Provided herein are methods and compositions for treating cancer, including cancer that is not responsive to immunotherapy.
Shanthi Ganesh
Filed: 3 Jan 19
Utility
Methods and compositions for the specific inhibition of Complement Component 5(C5) by double-stranded RNA
3 Oct 23
This invention relates to compounds, compositions, and methods useful for reducing C5 target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. Brown, Henryk T. Dudek
Filed: 17 Dec 20
Utility
Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA
11 Jul 23
This invention relates to compounds, compositions, and methods useful for reducing transthyretin (TTR) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob D. Brown, Henryk T. Dudek
Filed: 1 Jul 21
Utility
Methods and compositions for inhibiting expression of LDHA
30 May 23
This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.
Bob D. Brown, Henryk T. Dudek, Utsav Saxena, Natalie Pursell, Cheng Lai, Weimin Wang, Rachel Storr, Naim Nazef, Boyoung Kim
Filed: 16 Sep 20
Utility
Compositions and methods for inhibiting ALDH2 expression
30 May 23
This disclosure relates to oligonucleotides, compositions and methods useful for reducing ALDH2 expression, particularly in hepatocytes.
Utsav Saxena
Filed: 15 Jan 19
Utility
Compositions and methods for inhibiting mitochondria amidoxime reducing component 1 (MARC1) expression
23 May 23
Oligonucleotides are provided herein that inhibit MARC1 expression.
Henryk Dudek, Wen Han, Natalie Wayne Pursell, Chengjung Lai, William Geoffrey Haynes, Zhihao Ding
Filed: 27 May 22
Utility
Extended dicer substrate agents and methods for the specific inhibition of gene expression
25 Apr 23
The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell.
Bob Dale Brown
Filed: 12 Nov 20
Utility
Methods and compositions for treating bile duct paucity-associated conditions
25 Apr 23
This disclosure relates to oligonucleotides, compositions and methods useful for reducing CTNNB1 expression, particularly in hepatocytes, for the treatment of bile duct paucity-associated conditions.
Natalie Pursell, Cheng Lai
Filed: 15 Feb 19
Utility
Extended dicer substrate agents and methods for the specific inhibition of gene expression
7 Mar 23
The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell.
Bob Dale Brown
Filed: 8 Nov 21
Utility
Compositions and methods for inhibiting nuclear receptor subfamily 1 group H member 3 (NR1H3) expression
14 Feb 23
Oligonucleotides are provided herein that inhibit NR1H3 expression.
Utsav Saxena, Henryk Dudek, Natalie Wayne Pursell, Nicole Alexis Spiegelman, Markus Robert Latta, Birgitte Andersen
Filed: 19 Apr 22
Utility
Reducing beta-catenin expression to potentiate immunotherapy
7 Feb 23
Provided herein are methods and compositions for treating cancer, including cancer that is not responsive to immunotherapy.
Shanthi Ganesh, Marc Abrams
Filed: 28 Mar 18
Utility
Compositions and methods for inhibiting GYS2 expression
7 Feb 23
This disclosure relates to oligonucleotides, compositions and methods useful for reducing GYS2 expression, particularly in hepatocytes.
Bob D. Brown, Natalie Pursell, Henryk T. Dudek, Cheng Lai
Filed: 15 Feb 19
Utility
PCSK9 targeting oligonucleotides for treating hypercholesterolemia and related conditions
31 Jan 23
This disclosure relates to oligonucleotides, compositions and methods useful for reducing PCSK9 expression, particularly in hepatocytes.
Henryk T. Dudek, Jihye Park
Filed: 1 Apr 19
Utility
Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
22 Nov 22
Disclosed herein are methods for the treatment of cancer, comprising administering to a subject β-catenin nucleic acid inhibitor molecule and a therapeutically effective amount of an MEK inhibitor or a c-Myc nucleic acid inhibitor molecule.
Marc Abrams, Shanthi Ganesh
Filed: 29 Sep 20
Utility
Compositions and methods for inhibiting HMGB1 expression
25 Oct 22
This disclosure relates to oligonucleotides, compositions and methods useful for reducing HMGB1 expression, particularly in hepatocytes.
Marc Abrams, Girish Chopda, Jihye Park
Filed: 30 Apr 20
Utility
Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
4 Oct 22
This invention relates to compounds, compositions, and methods useful for reducing α-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Bob Dale Brown, Henryk T. Dudek
Filed: 10 Sep 21
Utility
Methods and compositions for the specific inhibition of KRAS by asymmetric double-stranded RNA
20 Sep 22
This invention relates to compounds, compositions, and methods useful for reducing KRAS target RNA and protein levels via use of Dicer substrate siRNA (DsiRNA) agents possessing asymmetric end structures.
Bob D. Brown
Filed: 22 Jun 20
Utility
4'-phosphate analogs and oligonucleotides comprising the same
16 Aug 22
Weimin Wang, Qingyi Li, Naim Nazef
Filed: 1 Sep 17